We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AKM-PREGABALIN, PHARMACOR PREGABALIN (Pharmacor Pty Ltd)
Product name
AKM-PREGABALIN, PHARMACOR PREGABALIN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
214 working days (255)
Active ingredients
Pregabalin
Registration type
New generic medicine
Indication
AKM-PREGABALIN, PHARMACOR PREGABALIN (capsules) is indicated for the treatment of neuropathic pain in adults. Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.